Your browser is no longer supported. Please, upgrade your browser.
Settings
MYOV Myovant Sciences Ltd. daily Stock Chart
MYOV [NYSE]
Myovant Sciences Ltd.
Index- P/E- EPS (ttm)-3.80 Insider Own49.90% Shs Outstand90.54M Perf Week-16.66%
Market Cap1.45B Forward P/E- EPS next Y-2.73 Insider Trans24.39% Shs Float32.29M Perf Month193.76%
Income-284.10M PEG- EPS next Q-0.80 Inst Own41.40% Short Float13.65% Perf Quarter125.81%
Sales- P/S- EPS this Y-71.10% Inst Trans-2.27% Short Ratio1.88 Perf Half Y80.09%
Book/sh0.19 P/B84.26 EPS next Y10.20% ROA-140.40% Target Price26.17 Perf Year-11.94%
Cash/sh1.74 P/C9.20 EPS next 5Y- ROE-768.50% 52W Range4.14 - 26.02 Perf YTD-2.44%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-38.47% Beta-
Dividend %- Quick Ratio2.80 Sales past 5Y- Gross Margin- 52W Low286.71% ATR1.52
Employees167 Current Ratio2.80 Sales Q/Q- Oper. Margin- RSI (14)68.26 Volatility8.76% 13.28%
OptionableYes Debt/Eq5.81 EPS Q/Q19.40% Profit Margin- Rel Volume0.56 Prev Close16.61
ShortableYes LT Debt/Eq5.32 EarningsNov 21 BMO Payout- Avg Volume2.35M Price16.01
Recom1.70 SMA2029.36% SMA50100.38% SMA20034.86% Volume1,305,391 Change-3.61%
Aug-28-19Initiated Goldman Buy
Aug-19-19Initiated SVB Leerink Outperform
May-30-19Resumed Citigroup Buy
Apr-12-19Initiated Evercore ISI Outperform
Feb-13-19Upgrade Barclays Equal Weight → Overweight $22 → $25
Oct-26-18Initiated Goldman Neutral $25
Sep-13-18Initiated JP Morgan Overweight $39
Apr-25-18Reiterated Citigroup Buy $17 → $44
Apr-05-18Downgrade Barclays Overweight → Equal Weight $18
Aug-17-17Initiated Evercore ISI Outperform $35
Nov-21-16Initiated Robert W. Baird Outperform $20
Nov-21-16Initiated JMP Securities Mkt Outperform
Nov-21-16Initiated Citigroup Buy
Nov-21-16Initiated Barclays Overweight $18
Dec-06-19 10:59AM  Should You Be Concerned About Myovant Sciences Ltd.'s (NYSE:MYOV) Historical Volatility? Simply Wall St.
Nov-29-19 12:15PM  Biotech Tops in November: Best ETFs & Stocks Zacks
08:54AM  Is the Options Market Predicting a Spike in Myovant (MYOV) Stock? Zacks
Nov-26-19 08:36AM  Myovant (MYOV) Catches Eye: Stock Jumps 6.7% Zacks
Nov-25-19 04:05PM  Myovant Sciences to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019 GlobeNewswire +6.74%
Nov-22-19 02:03PM  Fighting FOMO And Finding Profit In Consistency Benzinga +13.35%
Nov-20-19 09:31AM  Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More Zacks
09:22AM  Myovant Up on Successful Completion of Prostate Cancer Study Zacks
Nov-19-19 10:19AM  With prostate cancer trial done, Peninsula drug maker will ask for FDA approval early next year American City Business Journals +113.20%
08:59AM  UPDATE: Myovant stock rockets 79% premarket on news of positive trial of prostate cancer treatment MarketWatch
08:40AM  Myovant's Stock Soars After Relugolix Aces Late-Stage Study For Prostate Cancer Benzinga
07:56AM  The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout Benzinga
07:30AM  Myovant Sciences Announces 97% Response Rate in Positive Phase 3 HERO Study of Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer GlobeNewswire
Nov-18-19 04:05PM  Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, November 19 to Discuss Results from Phase 3 Study Evaluating Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer GlobeNewswire
Nov-12-19 08:20AM  Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2019 GlobeNewswire +5.79%
Nov-08-19 10:56AM  Myovant Sciences Ltd. (MYOV): Are Hedge Funds Right About This Stock? Insider Monkey +7.52%
Oct-31-19 11:50AM  Goldman Sachs: 3 Standout Healthcare Stocks That Could Double TipRanks +17.42%
09:20AM  Myovant Sciences Enters Landmark Agreement with Sumitomo Dainippon Pharma to Secure Major Financial Backing and Safeguards for Minority Shareholders GlobeNewswire
Oct-21-19 08:30AM  Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 1 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis GlobeNewswire
Oct-18-19 10:23AM  These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year American City Business Journals -8.84%
Oct-17-19 05:00AM  First-of-Its-Kind Nationwide Survey from Myovant Sciences and Evidation Health Captures Impact of Menstrual Stigma and Symptoms GlobeNewswire
05:00AM  Female Forward Together, a Cross-Sector Coalition, Announced to Advance Research, Education, and Action for Womens Health GlobeNewswire
Oct-16-19 07:06AM  The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch Benzinga
Oct-10-19 08:30AM  Myovant Sciences Announces Late-Breaking Oral Presentation of Phase 3 LIBERTY 1 & 2 Study Results at 2019 American Society for Reproductive Medicine Scientific Congress GlobeNewswire
Sep-17-19 09:20AM  Myovant Sciences Enters Oversold Territory Zacks
Sep-06-19 10:46AM  $3B package deal to push Peninsula company into arms of Japanese drugmaker American City Business Journals -6.59%
07:27AM  The Daily Biotech Pulse: European Nod For Roche, Takeda Recall, Neon Exults On Journal Publication Benzinga
03:01AM  Myovant Sciences Founding Shareholder Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create a Broad Strategic Alliance GlobeNewswire
Sep-05-19 07:10AM  Goldman Sachs Says These 3 Strong Buy Stocks Are Primed For Growth TipRanks
Aug-30-19 06:00AM  Myovant- Biotech Bet on Treating Endometriosis MoneyShow
Aug-27-19 10:02AM  How Much Are Myovant Sciences Ltd. (NYSE:MYOV) Insiders Spending On Buying Shares? Simply Wall St.
08:30AM  Myovant Sciences to Participate in Upcoming September Investor Conferences GlobeNewswire
Aug-20-19 08:30AM  Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 2 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis GlobeNewswire
Aug-06-19 04:05PM  Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for First Fiscal Quarter Ended June 30, 2019 GlobeNewswire
Aug-05-19 06:00AM  Myovant Sciences- Progress in Women's Health MoneyShow
Jul-23-19 05:36PM  CEO calls it an 'important day for women's health.' Wall Street appears unimpressed American City Business Journals
07:30AM  Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and Positive Results from Bioequivalence Study GlobeNewswire
Jul-22-19 04:01PM  Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, July 23rd to Discuss Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and from Bioequivalence Study GlobeNewswire
Jul-16-19 10:16AM  Health Care Digest: Why 2020 could be big for women's health, Trump's kidney order and more American City Business Journals
Jul-10-19 08:30AM  Myovant Sciences and Evidation Health Announce Partnership and Launch Digital Insights Study on Menstruation GlobeNewswire +6.65%
Jul-04-19 11:01AM  3 Hot Insider Trading Stocks To Boost Your Portfolio TipRanks
Jun-04-19 08:30AM  Myovant Sciences to Present at Upcoming June Investor Conferences GlobeNewswire +11.56%
May-31-19 02:31PM  Here's Why Myovant Sciences Jumped Today Motley Fool +9.34%
07:34AM  The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering Benzinga
May-30-19 09:01PM  Myovant Sciences Announces Pricing of $125 Million Public Offering of Common Shares GlobeNewswire -25.15%
May-29-19 04:16PM  Myovant Sciences Announces $100 Million Public Offering of Common Shares GlobeNewswire
May-24-19 04:05PM  Myovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019 GlobeNewswire
May-20-19 04:53PM  Health Care Digest: Cancer's show-and-tell meeting, a new biotech building rises and lupus patients' plea American City Business Journals
May-15-19 10:49AM  Biotech Stock Roundup: FDA Nod for REGN's Eylea in DR, Tie-Ups & Other Updates Zacks +5.30%
May-14-19 11:14AM  Myovant Shares Slide Despite Positive Late-Stage Data For Menstrual Bleeding Drug Benzinga -25.49%
08:10AM  Myovant stock up 1.6% after Phase 3 trial meets endpoints MarketWatch
08:07AM  Myovant Sciences' uterine fibroids combo therapy meets main goal in study Reuters
07:39AM  Introducing Myovant Sciences (NYSE:MYOV), The Stock That Dropped 23% In The Last Year Simply Wall St.
07:38AM  Myovant Sciences' uterine fibroids combo therapy meets main goal in study Reuters
07:30AM  Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids GlobeNewswire
May-13-19 04:16PM  Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, May 14th to Discuss Results from Phase 3 LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids GlobeNewswire
May-02-19 04:18PM  Heres What Hedge Funds Think About Myovant Sciences Ltd. (MYOV) Insider Monkey
Mar-05-19 08:30AM  Myovant Sciences to Present at Upcoming Investor Conferences PR Newswire
Feb-21-19 05:00AM  Myovant- "Value Creation" in Cancer Treatment MoneyShow
Feb-08-19 10:40AM  4 Disruptive Healthcare Stocks You've Never Heard Of Motley Fool
Feb-07-19 06:17PM  Myovant Sciences: Fiscal 3Q Earnings Snapshot Associated Press
04:05PM  Myovant Provides Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2018 PR Newswire
Jan-11-19 04:02PM  Andreas Halvorsen Plunges Into Biotech Company Myovant Sciences GuruFocus.com
Jan-02-19 08:00AM  Roivant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-20-18 08:30AM  Myovant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire
Nov-15-18 08:30AM  Myovant Sciences to Participate in Two Upcoming Investor Conferences PR Newswire
Nov-14-18 07:30AM  Recent Analysis Shows Atlas Financial, Royal Dutch Shell, Vaalco Energy, Myovant Sciences, Aerpio Pharmaceuticals, and Wheeler Real Estate Investment Trust Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-08-18 04:05PM  Myovant Provides Corporate Updates and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2018 PR Newswire
Nov-07-18 08:30AM  Myovant Strengthens Management Team and Adds New Directors to the Board PR Newswire -6.22%
Oct-24-18 08:30AM  Myovant Sciences Announces Completion of Enrollment in Phase 3 HERO Trial of Relugolix in Men with Advanced Prostate Cancer PR Newswire
Oct-10-18 01:45PM  Myovant Announces Presentation of Data from Phase 1 Trial of MVT-602 at 2018 American Society for Reproductive Medicine (ASRM) Annual Congress PR Newswire -6.56%
Oct-08-18 08:30AM  Myovant Sciences and Flo Health Partner to Develop Digital Tool to Screen Women for Heavy Menstrual Bleeding PR Newswire
Aug-28-18 08:30AM  Myovant Sciences to Participate in Two Upcoming Investor Conferences PR Newswire
Aug-07-18 04:30PM  Myovant Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2018 PR Newswire
Jul-12-18 09:09PM  Myovant Sciences Ltd. Announces Pricing of $75.0 Million Public Offering of Common Shares PR Newswire
Jul-11-18 04:05PM  Myovant Sciences Ltd. Announces $75 Million Public Offering of Common Shares PR Newswire
Jul-10-18 07:00AM  Myovant Sciences Announces Completion of Screening for Phase 3 LIBERTY 1 Study Evaluating Relugolix in Women with Uterine Fibroids PR Newswire
Jun-21-18 07:15AM  Blog Exposure - Biohaven Signs Royalty Funding and Stock Purchase Agreements with Royalty Pharma ACCESSWIRE
Jun-18-18 04:05PM  Myovant Sciences to Present at First Annual Roivant Pipeline Day PR Newswire
Jun-12-18 06:52AM  Myovant Sciences Ltd (NYSE:MYOV): Earnings Expected To Remain Subdued Simply Wall St.
Jun-07-18 05:21PM  Myovant Sciences: Fiscal 4Q Earnings Snapshot Associated Press
04:05PM  Myovant Provides Corporate Update and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2018 PR Newswire
Apr-20-18 08:00AM  Myovant Sciences and PERIOD. Inc. Launch Partnership Focused on Empowering Women to Elevate the Conversation Around Period Health PR Newswire
Mar-06-18 05:00PM  Myovant Sciences to Present at Upcoming Investor Conferences PR Newswire
Feb-13-18 05:08PM  Myovant Sciences reports 3Q loss Associated Press
04:05PM  Myovant Sciences Provides Corporate Update and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2017 PR Newswire
Jan-04-18 08:30AM  Myovant Sciences to Present at the 36th Annual J.P. Morgan Healthcare Conference PR Newswire +5.04%
Nov-21-17 08:30AM  Myovant Sciences to Participate in the Evercore ISI BioPharma Catalyst / Deep Dive Conference PR Newswire
Nov-13-17 04:05PM  Myovant Sciences Provides Corporate Update and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2017 PR Newswire
Nov-10-17 12:30PM  Roivant subsidiary stacks up positive Phase 3 news American City Business Journals
Nov-09-17 08:00AM  Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix for the Treatment of Pain Associated with Uterine Fibroids PR Newswire
Oct-16-17 08:45AM  Myovant Sciences Secures Flexible Financing Commitments of up to $140 Million PR Newswire
07:39AM  This drug may be able to treat both womens health disorders and prostate cancer MarketWatch
Oct-02-17 10:19PM  Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix Compared with Leuprorelin for the Treatment of Uterine Fibroids PR Newswire
Aug-31-17 08:00AM  Myovant Sciences Announces Upcoming Presentation at Baird's 2017 Global Healthcare Conference PR Newswire
Aug-30-17 10:56AM  QVT Financials Investments, Performance, Letters Insider Monkey
Aug-18-17 08:58AM  Strength Seen in Myovant Sciences (MYOV): Stock Soars 16.1% Zacks
Aug-10-17 04:30PM  Myovant Sciences Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2017 PR Newswire
Jul-19-17 04:05PM  Myovant Bolsters Executive Team with Key Management Appointments PR Newswire
Jul-10-17 08:45AM  Dermavant Sciences Appoints Dr. Jacqualyn Fouse as Executive Chairman PR Newswire
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Roivant Sciences Ltd.10% OwnerDec 04Buy17.0675,0001,279,31544,763,604Dec 04 06:08 PM
Roivant Sciences Ltd.10% OwnerDec 02Buy18.44179,1933,305,04144,688,604Dec 04 06:08 PM
Roivant Sciences Ltd.10% OwnerNov 25Buy15.003,500,00052,500,00044,509,411Nov 27 04:45 PM
Roivant Sciences Ltd.10% OwnerNov 21Buy11.89121,9061,449,10141,009,411Nov 22 09:28 PM
Roivant Sciences Ltd.10% OwnerNov 20Buy12.90121,9061,572,58740,887,505Nov 22 09:28 PM
Sebelius KathleenDirectorJun 12Buy8.965,00044,7845,000Jun 14 04:20 PM
KARBE FRANKPrincipal Fin'l & AccountingJun 11Buy9.108,00072,8008,000Jun 11 04:55 PM
QVT Associates GP LLC10% OwnerJun 04Buy8.252,424,24219,999,99740,765,599Jun 06 08:05 PM
SVF Investments (UK) Ltd10% OwnerJun 04Buy8.252,424,24219,999,99740,765,599Jun 06 06:30 PM
Machado Patrick10% OwnerJun 04Buy8.252,424,24219,999,99740,765,599Jun 06 06:30 PM
Dexxon Holdings Ltd.10% OwnerJun 04Buy8.252,424,24219,999,99740,765,599Jun 06 06:29 PM
Lo Andrew10% OwnerJun 04Buy8.252,424,24219,999,99740,765,599Jun 06 06:07 PM
Roivant Sciences Ltd.10% OwnerJun 04Buy8.252,424,24219,999,99740,765,599Jun 06 06:00 PM
VIKING GLOBAL INVESTORS LP10% OwnerJun 04Buy8.252,424,24219,999,99740,765,599Jun 13 03:47 PM
VIKING GLOBAL PERFORMANCE LLC10% OwnerJun 04Buy8.252,424,24219,999,99740,765,599Jun 13 03:45 PM
Arjona Ferreira Juan CamiloChief Medical OfficerFeb 15Sale21.152605,4999,740Feb 20 04:25 PM